Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Anxiety Disorders 1Adjustment Disorders 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × N-Methyl-3,4-methylenedioxyamphetamine × Clear all
NCT05584826 2026-05-04

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Sunstone Medical

Phase 2 Recruiting
20 enrolled

Adjustment Disorders, Neoplasms

NCT00252174 2017-11-14

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

Brigham and Women's Hospital

Phase 2 Terminated
2 enrolled 6 charts

Anxiety Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡